Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPhase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
Journal of Clinical Oncology, 10/09/09
Ravandi F et al. – The combination of alemtuzumab and pentostatin is feasible and effective in T-cell neoplasms. Although infections, including cytomegalovirus reactivation, are a concern, they may be minimized with adequate prophylactic antibiotic therapy.
Methods- 24 patients with a variety of T-cell leukemias and lymphomas treated with combination of alemtuzumab 30 mg intravenously (IV) three times weekly for up to 3 months and pentostatin 4 mg/m2 IV weekly for 4 weeks followed by alternate weekly administration up to 6 mos
- Prophylactic antibiotics including antiviral, antifungal, and antibacterial agents administered during treatment and for 2 months after completion
- Median age of patients was 57 years
- 8 patients previously untreated, and 16 had median of 2 prior therapies (range, 1 to 6 regimens)
- 13 patients responded to treatment (11 complete responses [CRs] and 2 partial responses)
- Overall response rate of 54%
- Median response duration was 19.5 mos
- Monoclonal T-cell receptor chain gene rearrangements detected by polymerase chain reaction in bone marrow of 20 of 22 evaluable patients
- Became negative in 5 of 7 evaluable patients in CR
- Opportunistic infections caused by pathogens associated with severe T-cell dysfunction common
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
microRNAs in acute myeloid leukemia: Expression patterns, correlations with genetic and clinical parameters, and prognostic significance
Genes, Chromosomes and Cancer, 12/19/09
Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia
Genes, Chromosomes and Cancer, 12/19/09
Primary cutaneous diffuse large B cell lymphoma relapsed solely as a huge lung tumor mimicking a primary pulmonary lymphoma
International Journal of Hematology, 12/17/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: A phase II study
International Journal of Cancer, 12/18/09
Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: Results from a randomized phase II study
Palliative Medicine, 12/18/09
A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial
Breast Cancer Research and Treatment, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor